Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cixutumumab in Metastatic Uveal Melanoma
NCT01413191Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2011
- Primary completion
- Mar 2013
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cixutumumab in Uveal melanoma (UM), sponsored by National Cancer Institute. Primary endpoints: Number of Participants With Response at 2 years and Safety and tolerability at 2 years. Started Aug 2011; status: completed.
02
Drugs
cixutumumab
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT01413191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01413191.